JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 177-182

  Silver, Richard T ^a   Vandris, Katherine ^a   Wang, Y Lynn ^b   Adriano, Fernando ^a   Jones, Amy V ^c   Christos, Paul J ^a   Cross, Nicholas C P ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Molecular Pathology Laboratory Network Inc   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Allele burden; JAK2V617F mutation; Myelofibrosis; Myeloproliferative disorders; Splenomegaly; Treatment of polycythemia vera

Indexed keywords

HYDROXYUREA; IMATINIB; JANUS KINASE 2; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HEMATOCRIT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK ASSESSMENT; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 2; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES;

EID: 78751706637     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.017     Document Type: Article

References (26)

1. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
2. Wang Y.L., Vandris K., Jones A., Cross N.C., Christos P., Adriano F., et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 2008, 22:1289.
3. V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007, 21:2074-2075.
4. Tefferi A., Lasho T.L., Schwager S.M., Strand J.S., Elliott M., Mesa R., et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006, 106:631-635.
5. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846.
6. Vannucchi A.M., Antonioli E., Guglielmelli P., Longo G., Pancrazzi A., Ponziani V., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21:1952-1959.
7. Vardiman J.W., Harris N.L., Brunning J.D. The WHO classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
8. Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008, 112:231-239.
9. V617F mutational load in patients with polycythemia vera (PV) measured by peripheral blood DNA is associated with disease severity. Blood (ASH Annual Meeting Abstracts) 2007, 110(November):2530.
10. Peterson P., Wasserman L.R. The natural history of polycythemia vera. Polycythemia and the myeloproliferative diseases 1995, 14-21. WB Saunders, Philadelphia. L.R. Wasserman, P.D. Berk, N.I. Berlin, W.B. Saunders (Eds.).
11. Manoharan A., Horsley R., Pitney W.R. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979, 43:185-190.
12. Silver R.T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 2006, 107:451-458.
13. Silver R.T. Treatment of polycythemia vera. Semin Thromb Hemost 2006, 32:437-442.
14. Barosi G., Birgegard G., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H.C., et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009, 113(20):4829-4833.
15. Landolfi R., Di Gennaro L., Barbui T., De Stefano V., Finazzi G., Marfisi R., et al. Leukocytosis as a major risk factor in patients with polycythemia vera. Blood 2007, 109:2446-2452.
16. V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007, 9:272-276.
17. Wang Y.L., Lee J.W., Kui J.S., Chadburn A., Cross N.C., Knowles D.M., et al. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematol 2007, 118:209-214.
18. Jones A.V., Silver R.T., Waghorn K., Curtis C., Kreil S., Zoi K., et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006, 107:3339-3341.
19. SPSS for Windows, Rel. 18.0.1. 2009. Chicago: SPSS Inc.
20. Baxter E.J., Scott L.M., Campbell P., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
21. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
22. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
23. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alfa therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22:1990-1998.
24. Silver R.T., Vandris K., Goldman J.J., Adriano F., Wang Y.L., Jones A.V., et al. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera (PV). Blood (ASH Annual Meeting Abstracts) 2009, 114(November):1908.
25. Girodon F., Schaeffer C., Cleyrat C., Mounier M., Lafont I., Dos Santos F., et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008, 93:1723-1727.
26. Sirhan S., Lasho T.L., Hanson C.A., Mesa R.A., Pardanani A., Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008, 83:63-65.